Cargando…

SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency

Disclosure: A.R. Hoffman: Consulting Fee; Self; Ascendis. S. Raveendran: Employee; Self; Ascendis Pharma. J. Manjelievskaia: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. A. Komirenko: Employee; Self; Ascendis Pharma. M. Bonafede: Employee; Self; Veradigm. Research Investigator; S...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman, Andrew R, Raveendran, Subhara, Manjelievskaia, Janna, Komirenko, Allison, Bonafede, Machaon, Winer, Isabelle, Cheng, Jennifer, Miner, Paul, Smith, Alden Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553983/
http://dx.doi.org/10.1210/jendso/bvad114.1344
_version_ 1785116304044195840
author Hoffman, Andrew R
Raveendran, Subhara
Manjelievskaia, Janna
Komirenko, Allison
Bonafede, Machaon
Winer, Isabelle
Cheng, Jennifer
Miner, Paul
Smith, Alden Raymond
author_facet Hoffman, Andrew R
Raveendran, Subhara
Manjelievskaia, Janna
Komirenko, Allison
Bonafede, Machaon
Winer, Isabelle
Cheng, Jennifer
Miner, Paul
Smith, Alden Raymond
author_sort Hoffman, Andrew R
collection PubMed
description Disclosure: A.R. Hoffman: Consulting Fee; Self; Ascendis. S. Raveendran: Employee; Self; Ascendis Pharma. J. Manjelievskaia: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. A. Komirenko: Employee; Self; Ascendis Pharma. M. Bonafede: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. Stock Owner; Self; Veradigm. I. Winer: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. J. Cheng: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. P. Miner: Employee; Self; Ascendis Pharma. A.R. Smith: Employee; Self; Ascendis Pharma. Introduction: Adult growth hormone deficiency (AGHD) is associated with an increased risk of morbidity and mortality, yet is known to be underdiagnosed and undertreated. Untreated or undertreated patients with AGHD can experience reduced quality of life, adverse changes in metabolic and cardiovascular (CV) function, and increased risk of other comorbidities. This study captured and described suspected AGHD cases based on a previously published algorithm in order to characterize the treatment rate and clinical burden of this disease. Methods: Using the Veradigm Network EHR database linked to administrative claims, this retrospective cohort study selected adult patients with suspected AGHD between 1/1/2017 and 12/31/2021 based on: hypopituitarism diagnosis or ≥1 diagnosis for related conditions, ≥3 pituitary hormone deficiencies, ≥3 replacement therapies with pituitary hormones or vasopressin, or ≥1 prescription for GH. Index date was based on the earliest qualifying event. Baseline demographics and clinical characteristics were assessed throughout the 12-month baseline period. Receipt of GH treatment was assessed throughout the 12-month baseline and 12-month follow-up periods. Results: Of the 51,588 patients with suspected AGHD, 59% were female, median age was 51 years, and 59% were White. About 3.2% had evidence of GH therapy during the study period. Among the 1,659 GH-treated patients, 40% were treated during both baseline and follow-up. Median age among treated patients was 48 years and 53% were male. At baseline, the top clinical comorbidities among the overall cohort were CV disease (52%), hyperlipidemia (47%), endocrine-related conditions (45%), mental health conditions (43%), and sleep disorders (29%). Treated adults had higher proportions of endocrine-related conditions (66% vs 44%), the most prevalent of which were hypopituitarism (38% vs 6%), hypothyroidism (37% vs 29%), and hypogonadism (27% vs 17%) compared to untreated. Higher proportions of CV disease (52% vs 36%), hyperlipidemia (47% vs 36%), obesity (35% vs 20%), diabetes mellitus (27% vs 15%), and liver disease (14% vs 11%) were observed in the untreated vs treated cohort. Prevalence of depression, anxiety, and sleep disorders was observed in about a third of both cohorts (treated and untreated). Conclusions: Most adults with suspected GHD remain untreated. Fewer than 4% of suspected AGHD patients in our study were treated with GH. Substantially higher proportions of clinical conditions related to metabolic and CV function were observed among the untreated cohort supporting the need for improved diagnosis and management of this disease. Presentation: Saturday, June 17, 2023
format Online
Article
Text
id pubmed-10553983
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105539832023-10-06 SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency Hoffman, Andrew R Raveendran, Subhara Manjelievskaia, Janna Komirenko, Allison Bonafede, Machaon Winer, Isabelle Cheng, Jennifer Miner, Paul Smith, Alden Raymond J Endocr Soc Neuroendocrinology And Pituitary Disclosure: A.R. Hoffman: Consulting Fee; Self; Ascendis. S. Raveendran: Employee; Self; Ascendis Pharma. J. Manjelievskaia: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. A. Komirenko: Employee; Self; Ascendis Pharma. M. Bonafede: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. Stock Owner; Self; Veradigm. I. Winer: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. J. Cheng: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. P. Miner: Employee; Self; Ascendis Pharma. A.R. Smith: Employee; Self; Ascendis Pharma. Introduction: Adult growth hormone deficiency (AGHD) is associated with an increased risk of morbidity and mortality, yet is known to be underdiagnosed and undertreated. Untreated or undertreated patients with AGHD can experience reduced quality of life, adverse changes in metabolic and cardiovascular (CV) function, and increased risk of other comorbidities. This study captured and described suspected AGHD cases based on a previously published algorithm in order to characterize the treatment rate and clinical burden of this disease. Methods: Using the Veradigm Network EHR database linked to administrative claims, this retrospective cohort study selected adult patients with suspected AGHD between 1/1/2017 and 12/31/2021 based on: hypopituitarism diagnosis or ≥1 diagnosis for related conditions, ≥3 pituitary hormone deficiencies, ≥3 replacement therapies with pituitary hormones or vasopressin, or ≥1 prescription for GH. Index date was based on the earliest qualifying event. Baseline demographics and clinical characteristics were assessed throughout the 12-month baseline period. Receipt of GH treatment was assessed throughout the 12-month baseline and 12-month follow-up periods. Results: Of the 51,588 patients with suspected AGHD, 59% were female, median age was 51 years, and 59% were White. About 3.2% had evidence of GH therapy during the study period. Among the 1,659 GH-treated patients, 40% were treated during both baseline and follow-up. Median age among treated patients was 48 years and 53% were male. At baseline, the top clinical comorbidities among the overall cohort were CV disease (52%), hyperlipidemia (47%), endocrine-related conditions (45%), mental health conditions (43%), and sleep disorders (29%). Treated adults had higher proportions of endocrine-related conditions (66% vs 44%), the most prevalent of which were hypopituitarism (38% vs 6%), hypothyroidism (37% vs 29%), and hypogonadism (27% vs 17%) compared to untreated. Higher proportions of CV disease (52% vs 36%), hyperlipidemia (47% vs 36%), obesity (35% vs 20%), diabetes mellitus (27% vs 15%), and liver disease (14% vs 11%) were observed in the untreated vs treated cohort. Prevalence of depression, anxiety, and sleep disorders was observed in about a third of both cohorts (treated and untreated). Conclusions: Most adults with suspected GHD remain untreated. Fewer than 4% of suspected AGHD patients in our study were treated with GH. Substantially higher proportions of clinical conditions related to metabolic and CV function were observed among the untreated cohort supporting the need for improved diagnosis and management of this disease. Presentation: Saturday, June 17, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10553983/ http://dx.doi.org/10.1210/jendso/bvad114.1344 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology And Pituitary
Hoffman, Andrew R
Raveendran, Subhara
Manjelievskaia, Janna
Komirenko, Allison
Bonafede, Machaon
Winer, Isabelle
Cheng, Jennifer
Miner, Paul
Smith, Alden Raymond
SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency
title SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency
title_full SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency
title_fullStr SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency
title_full_unstemmed SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency
title_short SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency
title_sort sat611 prevalence of comorbidities among treated and untreated adults with suspected growth hormone deficiency
topic Neuroendocrinology And Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553983/
http://dx.doi.org/10.1210/jendso/bvad114.1344
work_keys_str_mv AT hoffmanandrewr sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency
AT raveendransubhara sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency
AT manjelievskaiajanna sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency
AT komirenkoallison sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency
AT bonafedemachaon sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency
AT winerisabelle sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency
AT chengjennifer sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency
AT minerpaul sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency
AT smithaldenraymond sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency